Kashyap B. Patel, MD, has worn many hats in the struggle to broaden biosimilar access. He is an independent oncology practitioner, a member of the Community Oncology Alliance (COA), and a representative of International Oncology Network (ION) Solutions, a large drug purchasing organization. Bringing biosimilars to a broader population of patients has involved negotiations with payers, persistence on Capitol Hill, and education, he explains in an interview.
Biosimilars appear to be the only logistical solution to the rising cost of medicines, and 2 organizations in particular, the International Oncology Network (ION) Solutions and the Community Oncology Alliance (COA), have worked hard independently and on Capitol Hill to advance biosimilar-favorable legislation, according to Kashyap B. Patel, MD, a member of The Center for Biosimilars’ Advisory Board who spoke about biosimilar uptake in a recent interview.
“They both have put their full force behind supporting biosimilars,” Patel said of both organizations, in which he has been a participating member.
Patel, of Carolina Blood and Cancer Care Associates, in Lancaster, South Carolina, said his practice is a participant in the value-base-care—centered Oncology Care Model and has chosen to adopt new biosimilars immediately after they’re approved. “We’ve assimilated them very quickly into our practice. I see biosimilars as one of the only lifetime opportunities of reducing the cost of care,” he said.
He described the assimilation of these products in his practice as substantial, although he said that it has not been easy to do this, given that payers have not uniformly opened the door to coverage of these agents.
ION is a large purchasing cooperative that has formed a biosimilars committee, which provides education for providers, payers, and pharmacists. Patel participated in the formation of that committee, but said it was challenging to teach ION members about the distinction between generics and biosimilars.
An important issue in biosimilar access is the decision process that goes into the choice of biosimilars to offer participants in a care plan. In the case of infliximab and trastuzumab, there are multiple biosimilars on the market. “ION tends to be agnostic of the manufacturer,” Patel said about the purchasing organization’s choice of biosimilars. “I think they want to work with all the manufacturers who are willing. And there’s going to be regional variation based on the payer coverage.”
ION as an intermediary works to establish manufacturer relationships and leaves it up to the physicians to decide which of the available biosimilars to use. However, “ION has chosen to go with supporting biosimilars as a part of a social responsibility,” Patel said.
COA is an organization of community oncology practices that, while not acting as a contracting representative for biosimilars and other drugs, works to promote the availability of biosimilars, Patel said. “Our role at COA is just to make sure that we bring every toolkit for our teams’ colleagues and work with the payers to help them understand the relevance of the biosimilars in addressing [Medicare] Part B drug price [issues]. We want to do everything possible we can to reduce the drug price in conjunction with the government, Senate, Congress, and payers.”
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Pipelines and Preparation: How the US Can Prepare for More RA Biosimilars
April 16th 2023What can practices do to prepare for all the biosimilars to treat rheumatoid arthritis (RA) coming down the pipeline? And how can they ensure that the lower-than-anticipated adoption rates for infliximab biosimilars are not repeated? Robert Zutaut, RPh, from McKesson Provider Solutions, tackles all this and more on this episode of Not So Different.
Physician and Patient Perspectives After Starting or Switching to Amgevita in IBD
March 23rd 2024A real-world study surveying physicians and patients on adalimumab biosimilar ABP 501 (Amgevita) in inflammatory bowel disease (IBD) found both patients initiating ABP 501 and those who had switched from the reference product had higher satisfaction levels.